[5] Bruits may be heard over the carotid or subclavian areas, or rarely over the orbits. Giant cell arteritis is a systemic vasculitis and careful attention should be given to the examination of ...

Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, expectations were $1.8. Operator: Good morning and good afternoon, and welcome to the ...

And over the course of year, we expect two Phase 3 readouts in giant cell arteritis and polymyalgia ... broad pipeline across our four therapeutic areas across our key platforms and our goal ...

The biosimilar landscape continues to expand, with 2024 delivering a wave of exciting approvals across multiple therapeutic areas. Last year alone saw ... be used to treat rheumatoid arthritis, giant ...

Central hypofluorescent areas which appeared as dark regions on FFA imaging ... diagnosis for older adults with a history of visual loss and headache is giant cell arteritis (GCA).3 However, even with ...

Patients with predominantly cranial vs isolated extracranial GCA phenotypes present with different patterns of arterial involvement on 18F-FDG PET-CT scans.

Mortality rates among patients with GCA in Spain are similar to that of the general population, with older age and male sex linked to higher mortality.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release ...

Objectives Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in ...

France Objectives To evaluate the effect of adding a 10-week treatment of adalimumab to a standardised treatment with corticosteroids on the ability to taper more rapidly corticosteroid doses in ...

The FDA has granted approval for Celltrion's Avtozma in both IV and SC formulations as Actemra biosimilar for treating ...

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...